Antibodies against annexin A5: Detection pitfalls and clinical associations

References

• Rand JH. Annexinopathies—a new class of diseases. NEJM 1999; 340: 1035–1036
   PubMedGoogle Scholar
• Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29–37
   PubMed Web of Science ®Google Scholar
• Moss SE, Morgan RO. The annexins. Genome Biol 2004; 5: 219
   PubMed Web of Science ®Google Scholar
• Human Gene Nomenclature Committee [Internet]. Morgan RO, Fernandez M-P. Classification and Nomenclature Revision Proposals for 160 Members of the Annexin Gene Superfamily, Based on Molecular Phylogeny and Comparative Genomic Analysis, Available from: http://www.gene.ucl.ac.uk/nomenclature
   Google Scholar
• Dubois T, Oudinet JP, Mira JP, Russo-Marie F. Annexins and protein kinases C. Biochim Biophys Acta 1996; 1313: 290–294
   PubMed Web of Science ®Google Scholar
• Huber R, Römisch J, Pâques E. The crystal and molecular structure of human annexin V, an anticoagulant protein that binds to calcium and membranes. EMBO J 1990; 9: 3867–3874
   PubMed Web of Science ®Google Scholar
• Jin M, Smith C, Hsieh HY, Gibson DF, Tait JF. Essential role of B-helix calcium binding sites in annexin V-membrane binding. J Biol Chem 2004; 279(39)40351–40357
   PubMedGoogle Scholar
• Benz J, Hofmann A. Annexins: From structure to function. Biol Chem 1997; 378: 177–183
   PubMedGoogle Scholar
• Krikum G, Lockwood CJ, Wu XX, Zhou XD, Guller S, Calandri C, et al. The expression of the plancental anticoagulant protein, annexin V, by villous trophoblasts: Immunolocalization and in vitro regulation. Placenta 1994; 15: 601–612
   PubMedGoogle Scholar
• van Heerde WL, de Groot PG, Reutelingsperger CPM. The Complexity of the phospholipid binding protein annexin V. Thromb Haemostas 1995; 73: 172–179
   PubMed Web of Science ®Google Scholar
• Pigault C, Follenius-Wund A, Schmutz M, Freyssinet JM, Brisston A. Formation of two dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol 1994; 235: 199–208
   Google Scholar
• Rand JH, Wu XX. The annexins: A target for antiphospholipid antibodies. Elsevier Science B.V. 2002
   Google Scholar
• Rand JH, Wu XX, Quinn AS, Chen PP, McCrae KR, Bovill EG, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: Evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163: 1193–1200
   PubMed Web of Science ®Google Scholar
• Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Swedenborg J, Fei GZ, Frostegard J. Decreased binding of annexin v to endothelial cells: A potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25(1)198–203
   PubMed Web of Science ®Google Scholar
• Ida M, Satoh A, Matsumoto I, Kojima-Aikawa K. Human annexin V binds to sulfatide: Contribution to regulation of blood coagulation. J Biochem (Tokyo) 2004; 135(5)583–588
   PubMedGoogle Scholar
• Capila I, Hernáiz MJ, Mo YD, Mealy TR, Campos B, Lindhardt RJ, et al. Annexin V-heparin oligosaccharide complex suggests heparan sulfate-mediated assembly on cell surfaces. Structure 2001; 9: 57–64
   PubMedGoogle Scholar
• Russo-Marie F. Annexin V and phospholipid metabolism. Clin Chem Lab Med 1990; 37: 2287–2291
   Google Scholar
• Reutelingsperger CPM, Van Heerde WL. Annexin V the regulator of phosphatidylserine-catalyzed inflammation and coagulaton during apoptosis. Cell Mol Life Sci 1997; 53: 527–532
   PubMed Web of Science ®Google Scholar
• Ravassa S, Bennaghmouch A, Kenis H, Lindhout T, Hackeng T, Narula J, Hofstra L, Reutelingsperger C. Annexin A5 downregulates surface expression of tissue factor: A novel mechanism of regulating the membrane receptor repertoire. J Biol Chem 2005; 280: 6028–6035
   PubMedGoogle Scholar
• Rojas E, Pollard HB, Haigler HT, Parra C, Burns AL. Calcium-activated endonexin II forms calcium channels across acidic phospholipid bilayer membranes. J Biol Chem 1990; 265: 21207–21215
   PubMed Web of Science ®Google Scholar
• Berendes R, Voges D, Demange D, Huber P, Burger A. Structure-functon analysis of the ion channel selectivity filter in human annexin V. Science 1993; 262: 427–430
   PubMedGoogle Scholar
• Liemann S, Benz J, Burger A, Voges D, Hofmann A, Huber R, et al. Structural and functional characterisation of the voltage sensor in the ion channel human annexin V. J Mol Biol 1996; 258: 555–561
   PubMedGoogle Scholar
• Kirsch T, Nah HD, Demuth DR, Harrison G, Golub EE, Adams SL, et al. Annexin V-mediated calcium flux across membranes is dependent on the lipid composition: Implications for cartilage mineralization. Biochemistry 1997; 36: 3359–3367
   PubMed Web of Science ®Google Scholar
• Brachvogel B, Dikschas J, Moch H, Welzel H, von der Mark K, Hofmann C, Poschl E. Annexin A5 is not essential for skeletal development. Mol Cell Biol 2003; 23: 2907–2913
   PubMed Web of Science ®Google Scholar
• Haut Donahue TL, Genetos DC, Jacobs CR, Donahue HJ, Yellowley CE. Annexin V disruption impairs mechanically induced calcium signaling in osteoblastic cells. Bone 2004; 35(3)656–663
   PubMedGoogle Scholar
• Wang X, Kaetzel MA, Yoo SE, Kim PS, Dedman JR. Ligand-regulated secretion of recombinant annexin V from cultured thyroid epithelial cells. Am J Physiol Cell Physiol 2002; 282: C1313–C1321
   Google Scholar
• Satoh A, Suzuki K, Takayama E, Kojima K, Hidaka T, Kawakami M, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999; 26: 1715–1720
   PubMedGoogle Scholar
• Bandorowicz- Pikula J, Siroksi AF, Bialkowska K, Sobota A. Interaction of annexins IV and V with phosphatidylserine in the presence of Ca2+: Monolayer and proteolitic study. Mol Membr Biol 1996; 13: 241–251
   PubMedGoogle Scholar
• de la Fuente M, Ossa CG. Binding to phosphatidylserine membranes causes a conformational change in the concave face of annexin I. Biophys J 1997; 72: 283–287
   Google Scholar
• Čučnik S, Kveder T, Božič B. Heterogeneity of anti-prothrombin antibodies detected by different ELISAs. Lupus 2002; 11: 578
   Google Scholar
• Gašperšič N, Kveder T, Božič B. The influence of calcium ions on the detection of anti-annexin V antibodies. Lupus 2002; 11: 591
   Google Scholar
• Concha NO, Head JF, Kaetzel MA, Dedman JR, Seaton B. Annexin V forms calcium -dependent trimeric units on phospholipid vesicles. FEBS Lett 1992; 314: 159–162
   PubMed Web of Science ®Google Scholar
• Sopkova J, Renouard M, Lewit-Bentley A. The cristal-structure of a new high-calcium form of annexin V. J Mol Biol 1993; 234: 816–825
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Arai T, Izumi S, Sugi T, McIntyre JA. Tsunehisha Makino. Anti-annexin V antibodies in patients with early pregnancy loss or implantation failures. Fertil Steril 2001; 76: 694–699
   PubMedGoogle Scholar
• Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hemathol 1994; 47: 56–58
   PubMed Web of Science ®Google Scholar
• Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patiets with systemic autoimmune diseases. J Rheumatol 2000; 27: 924–929
   PubMedGoogle Scholar
• Dubois T, Bisagni-Faure A, Coste J, Mavoungou E, Menkes CJ, Russo-Marie F, et al. High levels of antibodies to annexin V and VI in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1930–1934
   Google Scholar
• Rodriguez-Garcia MI, Fernandez JA, Rodrigez A, Fernandez MP, Gutierrez C, Torre-Alonso JC. Annexin V autoantibodies in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 895–900
   PubMedGoogle Scholar
• Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Ikeda Y. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997; 54: 209–213
   PubMed Web of Science ®Google Scholar
• Gris JC, Quéré I, Sanmarco M, Boutiere B, Mercier E, Amiral J, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. Thromb Haemost 2000; 84: 228–236
   PubMed Web of Science ®Google Scholar
• Arnold J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H. Anti- beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriages. Br J Haematol 2001; 113: 911–914
   PubMed Web of Science ®Google Scholar
• Gašperšič N, Kveder T, Božič B. The influence of different ELISA incubations on the binding of low avidity Anti-annexin V antibodies. Autoimmun Rev 2002; 1: 89
   PubMedGoogle Scholar
• Matsuda J, Gotoh M, Saitoh N, Gohchi K, Tsukamoto M, Yamamoto T. Anti-annexin antibody in sera of patients with habitual fetal loss or preeclampsia. Throm Res 1994; 75: 105–106
   PubMedGoogle Scholar
• Gris JC, Perneger TV, Quere I, Mercier E, Fabbro-Peray P, Lavigne-Lissalde G, et al. Antiphospholipid / antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocystein as risk factor for first pregnancy loss: A matched case-control study. Blood 2003; 102: 3504–3513
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R. Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 2005; 129(1)61–68
   PubMedGoogle Scholar
• Bose P, Black S, Kadyrov M, Bartz C, Shlebak A, Regan L, Huppertz B. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004; 191: 2125–2131
   PubMed Web of Science ®Google Scholar
• Bose P, Black S, Kadyrov M, Bartz C, Weissenborn U, Neulen J, Regan L, Huppertz B. Heparin and aspirin attenuate placental apoptosis in vitro: Implications for early pregnancy failure. Am J Obstet Gynecol 2005; 192: 23–30
   PubMed Web of Science ®Google Scholar
• Nojima J, Kuratsune H, Suehisa E, Futsukichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47: 1008–1015
   PubMed Web of Science ®Google Scholar
• Sugiura K, Muro Y. Anti-annexin V antibodies and digital ischemia in patients with scleroderma. J Rheumatol 1999; 26: 168–172
   Google Scholar
• Ogawa H, Zhao D, Dlott JS, Cameron GS, Yamazaki M, Hata T, et al. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am Soc Clin Pathol 2000; 114: 619–628
   PubMedGoogle Scholar
• Ishikura K, Wada H, Kamikura Y, Hattori K, Fukuzawa T, Yamada N, Nakamura M, Nobori T, Nakano T. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol. 2004; 76(4)338–342
   PubMedGoogle Scholar
• Gašperšič N, Rot U, Čučnik S, Božič B, Kveder T, Rozman B. Low prevalence of anti-phopsholipid antibodies in a series of young patients with cerebrovascular disease. Clin Exp Rheumatol 2003; 21: 680
   PubMedGoogle Scholar
• Gašperšič N, Rot U, Čučnik S, Božič B, Kveder T, Rozman B. Anti-annexin V antibodies in patients with cerebrovascular disease. Ann Rheum Dis 2003; 62: 188–189
   PubMedGoogle Scholar
• Tripathy NK, Sinha N, Nityanand S. Anti-annexin V antibodies in Takayasu's arteritis: Prevalence and relationship with disease activity. Clin Exp Immunol 2003; 134(2)360–364
   PubMedGoogle Scholar